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Introduction: Analgesic nephropathy is a disease resulting from the frequent use of combi-
nations of analgesic medications over many years, leading to significant impairment of renal 
function. The observation of a large number of cases of renal failure in patients abusing analgesic 
mixtures containing phenacetin led to the initial recognition of the nephrotoxicity from the use 
of analgesics. Phenacetin was subsequently exclusively blamed for this disease. However, the 
role of a single analgesic as a sole cause of analgesic nephropathy was challenged, and a number 
of researchers have since attempted to determine the extent of involvement of other analgesics 
including nonsteroidal anti-inflammatory drugs (NSAIDs), aspirin, and paracetamol.
Case presentation: We present the case of an 83-year-old woman with a history of NSAID-
induced nephropathy with poor pain control and reluctance to use paracetamol. We attempt to 
briefly review the evidence of paracetamol being implicated in the development of analgesic-
induced nephropathy.
Conclusion: There is a lack of concrete data regarding causative analgesics, including par-
acetamol. Patients should therefore not be withheld paracetamol, an effective and commonly 
recommended agent, for fear of worsening renal function.
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Introduction
We present a case of poor pain control and reluctance to use paracetamol in an elderly 
patient who had a history of nonsteroidal anti-inflammatory drug (NSAID)-induced 
nephropathy. We also attempt to briefly review the evidence of paracetamol being 
implicated in the development of analgesic-induced nephropathy.
Case details
Mrs MJ (83 years old) was referred for a routine Home Medicines Review in view of 
her multiple medications (Table 1). Home Medicines Review is a government-funded 
program in Australia that allows a pharmacist to review patients’ medications at their 
homes and make recommendations to their general practitioners.1,2
Mrs MJ’s medical history included: atrial fibrillation, analgesic nephropathy (AN), 
chronic kidney disease (stage 3, estimated glomerular filtration rate 60 mL/min/1.73 m2), 
gastroesophageal reflux disease, vitamin B
12
 deficiency, hypertension, hypercholes-
terolemia, hyperhomocysteinemia, hypothyroidism, myocardial infarction (two in the 
1970s), degenerative spondylolisthesis, and transient ischemic attack.
At review, Mrs MJ described persistent back pain, but was reluctant to take par-
acetamol, due to her renal disease and previously documented analgesic-induced 
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nephropathy in 1999. The patient had been told by health 
professionals to be careful with “some painkillers” to avoid 
further kidney damage, and subsequently had chosen to avoid 
paracetamol. The patient was unsure which health profes-
sional had told her to avoid paracetamol, but had decided it 
would be prudent to avoid “all painkillers”, and she could 
not recall a health professional telling her paracetamol was 
safe. Further, it was documented that the patient had previ-
ously experienced acute renal failure from the use of an 
NSAID. The patient was unsure which NSAID had caused 
her acute kidney failure, and it was not documented in her 
medical history.
Discussion
analgesic nephropathy
Chronic pain is a treatable condition that at any one point in 
time affects 20%–46% of community-dwelling older adults 
and 28%–73% of residents in aged-care facilities.3 A number 
of practice guidelines and literature reviews relating to the 
management of chronic pain in the elderly exist, with para-
cetamol being the first-line management option.3,4
A daily dose of both analgesic and anti-inflammatory 
medications is common practice among millions of patients 
experiencing chronic pain.5 Paracetamol is used alongside 
NSAIDs to assist in managing inflammatory conditions, 
such as gout or rheumatoid arthritis.6 NSAIDs are more 
effective than paracetamol for persistent inflammatory 
pain; however, they are associated with gastrointestinal side 
effects (eg, ulcers, bleeding), cardiovascular side effects 
(eg, hypertension, exacerbation of heart failure), and wors-
ening of chronic renal failure.3,4 NSAIDs are best avoided 
in the elderly despite their efficacy, and if they are required 
to use them, they should be given in the lowest possible 
dose for the shortest period.3 The long-term effects of other 
analgesics (particularly paracetamol) on the kidneys have 
been debated at length.7,8
Currently, there are two recognized forms of AN: NSAID-
associated nephropathy and classic AN. NSAID-induced neph-
ropathy is a widely reviewed condition.9 The nephrotoxicity of 
NSAIDs is mediated via nonspecific blocking of cyclooxyge-
nase, subsequent inhibition of prostaglandin synthesis leading 
to vasoconstriction, and reversible renal impairment in volume-
contracted states.9 This may lead to acute tubular necrosis and 
acute renal failure. NSAIDs also produce interstitial nephritis 
and papillary necrosis, resulting in chronic renal failure.9
The observation of large numbers of cases of renal 
failure in patients abusing analgesic mixtures containing 
phenacetin (termed phenacetin nephropathy) led to the initial 
recognition of nephrotoxicity from the use of analgesics.10 
However, the role of a single analgesic as a sole cause of AN 
was challenged, leading to the redefinition of AN in 1996 as 
“a disease resulting from the frequent use of combinations 
of analgesic medications over many years, usually codeine 
or caffeine”.10
Phenacetin was introduced as an analgesic in 1887, soon 
followed by paracetamol in 1893.11 Phenacetin was popular 
due to its long duration of action; however, it had weaker 
antipyretic effects when compared to paracetamol.11 It took 
scientists nearly 50 years to discover that paracetamol is the 
major metabolite of phenacetin, thus accounting for phena-
cetin’s analgesic effect (Figure 1).11
In the 1970s, AN as a cause of end-stage renal disease 
reached its peak in Australia, with the condition being respon-
sible for an estimated 20% of patients requiring renal 
replacement therapy.12 As a response to this, phenacetin was 
removed from Vincents® and Bex® (the most frequently used 
analgesic products) in 1967 and 1975, respectively.13 In 1977, 
phenacetin was legally banned from all medical preparations 
in Australia, and all over-the-counter combination analge-
sic products were banned in 1979.13 Phenacetin was later 
removed from the Canadian market in 1978, and in 1983 
from the US.14,15 Similarly, phenacetin was banned from the 
UK in 1980, and in Belgium phenacetin was removed from 
the two most frequently “abused” preparations in 1972 and 
1981, followed by a total legal ban in 1988.15,16 Since this 
time, the exclusive role of phenacetin has been questioned 
in the development of nephropathy.
Researchers have proposed that paracetamol, not 
phenacetin, accumulated in the renal papilla, and in animal 
Table 1 Mrs MJ’s medication profile
Medication Dose and frequency
amlodipine 5 mg one tablet daily
Irbesartan 300 mg one tablet daily
sotalol 80 mg Half a tablet twice daily
Moxonidine 200 μg one tablet daily
simvastatin 40 mg one tablet at night
Dabigatran 150 mg one tablet twice a day
Calcium 600 mg one tablet daily
thyroxine 50 μg one tablet daily
pantoprazole 40 mg one tablet when required 
(usually once a week)
paracetamol sR 665 mg Not using (prescribed one 
tablet three times a day)
paracetamol 500 mg/codeine 30 mg one tablet at night
Folic acid 0.5 mg one tablet daily
Vitamin B6 240 mg one tablet daily
Vitamin B12 100 μg one tablet daily
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 experiments phenacetin appeared to be less nephrotoxic than 
the other analgesics.17 Further, the withdrawal of phenacetin 
in Australia in 1977 did not result in a decline of AN, as 
illustrated in Figure 2.12,18 On the contrary, a surge in the 
incidence of AN was noted for some years before a reduction. 
These differences presumably resulted from the misdiagnosis 
of NSAID-induced nephropathy.18
Several case-control studies have reported associations 
between chronic renal failure and other analgesic prepara-
tions, including aspirin, antipyretics, and NSAIDs in com-
bination with caffeine, codeine, and/or barbiturates.19 The 
research regarding the effects of paracetamol on AN appear 
to be inconclusive.
Perneger et al investigated 716 patients with renal 
failure, and concluded that increased paracetamol use 
was associated with an enhanced risk of renal failure in a 
dose-dependent manner.20 Approximately 9% of renal fail-
ure cases were attributable to increased paracetamol use.20 
However, this study failed to adjust for the potential for 
patients using paracetamol to be concurrently using either 
phenacetin or NSAIDs when assessing association with renal 
failure.20
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Figure 1 Metabolism of phenacetin to paracetamol and further metabolites.
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Figure 2 Incidence of analgesic nephropathy (aN) in patients admitted for renal replacement therapy in New south Wales (NsW), australia and Flanders, Belgium. 
Note: Republished with permission of J Am Soc Nephrol from trends of analgesic nephropathy in two high-endemic regions with different legislation, Michielsen p, 
De schepper p, 12(3):550–556, 2001; permission conveyed through Copyright Clearance Center, Inc.26
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A major review by Delzell and Shapiro highlighted that 
most of the epidemiological evidence investigating AN has 
been unsatisfactory, and the research using animal models 
was inconsistent and not translatable to humans.21 Another 
review published in 2000 found no evidence between non-
phenacetin combined analgesics and nephropathy.22 A 2001 
study attempted to adjust for the use of other analgesics, 
including phenacetin, and evaluate paracetamol and aspirin 
use in relation to chronic renal disease.23 This study found 
that the regular use of paracetamol (at least twice a week for 
2 months) increased the risk of developing chronic renal fail-
ure (2.5-fold increase compared to nonusers). However, con-
sumption of these analgesics for conditions that predisposed 
patients to renal failure may have resulted in some bias.23
Mihatsch et al (n=616, autopsy examination of adult 
kidneys) found compelling evidence demonstrating non-
phenacetin analgesics are not responsible for AN, citing a 
significant decline in the prevalence of AN from ∼4% in 1980 
to 0.2% in 2000 (20 years after the removal of phenacetin 
from the analgesic market). Also, Kelkar et al conducted a 
retrospective case-control study of medical and pharmacy 
claims of a sample of 4,742 cases of renal disease, compar-
ing chronic versus acute paracetamol use and renal disease.24 
This study further confirmed that there was not a significant 
increase in risk for AN in patients exposed to accumulative 
dosage of at least 1 kg of paracetamol in the preindex year.24 
Researchers, however, were unable to assess use of over-the-
counter paracetamol, which would likely have strengthened 
results.24 Currently in Australia, paracetamol is available for 
purchase as an unscheduled medication as 500 mg tablets in 
packets of 20 tablets or less.25 The sale of larger quantities 
and combination products, such as narcotic and decongestant 
preparations, are more highly regulated, and are required to 
be sold by pharmacies.25
In response to the lack of concrete data regarding caus-
ative analgesics, a peer-review committee was selected by 
the regulatory authorities of Germany, Switzerland, and 
Austria to determine the relationship between nonphenacetin 
analgesics and AN.22 The committee concluded that previ-
ously published studies to date had major flaws and failed to 
establish the association of analgesics other than phenacetin 
leading to chronic renal disease.22 In our view, patients should 
not be withheld an effective and commonly recommended 
analgesic agent for fear of worsening renal function.
Conclusion
We have presented a case of a patient who was concerned 
about an adverse side effect of paracetamol that has not been 
clearly established in the literature. The patient was reassured 
that paracetamol was safe. At follow-up, our patient reported 
recommencing paracetamol (665 mg three times a day), with 
improvement in back pain control without deterioration of 
renal function.
Disclosure
The authors report no conflicts of interest in this work.
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